Phase II Trial of High-Dose Rituximab with High-dose Cytarabine Mobilization Therapy and High-Dose Thiotepa, Busulfan, and Cyclophosphamide (R-TBC) Autologous Stem Cell Transplant in Patients with CNS Involvement by Non-Hodgkin Lymphoma

Background High-dose thiotepa, busulfan, and cyclophosphamide (TBC) with autologous stem cell transplantation (ASCT) has been used in patients with central nervous system (CNS) involvement by non-Hodgkin lymphoma (NHL). Despite limited penetration into the CNS, rituximab (R) is active in primary CNS NHL. We therefore combined high-dose R with TBC for ASCT in patients with CNS NHL.